• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 31, 2024
Distillery Therapeutics

Controlling SPHK1 and SPHK2 activity for heart failure

Read More
BioCentury | Sep 16, 2021
Product Development

Quick Takes: FDA approves Takeda’s Exkivity for NSCLC with specific mutation

Plus: an ALS reversal, Theravance downsizing, Calliditas still first in line, EU earmarks €50B for HERA and more
Read More
BioCentury | Aug 27, 2021
Translation in Brief

Stanford tech advances RNA structure prediction

Plus: Denali, Editas, Fred Hutchinson and more
Read More
BioCentury | Sep 9, 2020
Product Development

COVID-19 roundup: SpyBiotech-Serum Institute of India send HBV-based COVID-19 vaccine to clinic; plus Vaxart, Inovio-Thermo Fisher and RedHill

SpyBiotech, Serum Institute of India start vaccine trialU.K. biotech SpyBiotech Ltd. and its partner the Serum Institute of India on Tuesday started a Phase I/II trial of a virus-like particle
Read More
BioCentury | Apr 7, 2020
Product Development

COVID-19 roundup: Inovio starts vaccine trial; plus updates from RedHill, Hope, CytoDyn, Gilead, Takeda, AACR and UNC-Emory

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
Read More
BioCentury | Aug 29, 2019
Distillery Therapeutics

SPHK1 in T cells identified as melanoma target

Read More
BioCentury | Feb 22, 2019
Targets & Mechanisms

Expansion into TNBC

How RNA-binding small molecules could sensitize TNBC to targeted therapies
Read More
BioCentury | Feb 11, 2019
Preclinical News

Scripps miRNA flips HER2-negative tumors to HER2-positive

Read More
BioCentury | Nov 30, 2018
Clinical News

RedHill's Yeliva yields one partial response in MM patient in preliminary Phase Ib data

Read More
BioCentury | May 23, 2018
Distillery Therapeutics

Neurology

Read More
Items per page:
1 - 10 of 49